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ABSTRACT
SIMPSON, A. J., S. HORNE, P. SHARP, R. SHARPS, and P. KIPPELEN. Effect of Creatine Supplementation on the Airways of Youth Elite
Soccer Players.Med. Sci. Sports Exerc., Vol. 51, No. 8, pp. 1582–1590, 2019. Introduction:Owing to its well-established ergogenic poten-
tial, creatine is a highly popular food supplement in sports. As an oral supplement, creatine is considered safe and ethical. However, no data
exist on the safety of creatine on lung function in athletes. The aim of this project was to evaluate the effects of a standard course of creatine on
the airways of youth elite athletes. Methods: Nineteen elite soccer players, 16–21 yr old, completed a stratified, randomized, double-blind,
placebo-controlled, parallel-group trial. The creatine group (n = 9) ingested 0.3 g·kg−1⋅d−1 of creatine monohydrate (CM) for 1 wk (loading
phase) and 5 g·d−1 for 7 wk (maintenance phase), and the placebo group (n = 10) received the same dosages of maltodextrin. Airway inflam-
mation (assessed by exhaled nitric oxide, FENO) and airway responsiveness (to dry air hyperpnoea) were measured pre- and
postsupplementation. Results:Mild, unfavorable changes in FENO were noticed by trend over the supplementation period in the CM group
only (P = 0.056 for interaction, η2 = 0.199), with a mean group change of 9 ± 13 ppb in the CM group versus−5 ± 16 ppb in the placebo group
(P = 0.056, d = 0.695). Further, the maximum fall in forced expiratory volume in 1 s after dry air hyperpnoea was larger by trend
postsupplementation in the CM group compared with the placebo group: 9.7% ± 7.5% vs 4.4% ± 1.4%, respectively (P = 0.070,
d = 0.975). These adverse effects were more pronounced when atopic players only (n = 15) were considered. Conclusion: On the basis of
the observed trends and medium to large effect sizes, we cannot exclude that creatine supplementation has an adverse effect on the airways
of elite athletes, particularly in those with allergic sensitization. Further safety profiling of the ergogenic food supplement is warranted.
Key Words: CREATINE MONOHYDRATE, FOOTBALL, AIRWAY INFLAMMATION, AIRWAY HYPERRESPONSIVENESS,
EXHALED NITRIC OXIDE, EUCAPNIC VOLUNTARY HYPERPNOEA
Creatine is one of the most popular food supplementsused by athletes (1); it is used in a wide variety ofsports and at all levels (e.g., about a third of English
professional soccer players [2] and the same percentage of
American children and adolescents [3] declare using the sup-
plement). The popularity of creatine stems from the fact that
the ergogenic potential of creatine is supported by strong
scientific evidence (1) and its mechanisms of action are well
understood. Since the early 1990s (4), studies have consistently
shown that creatine supplementation raises intramuscular crea-
tine stores, thereby helping to maintain adenosine triphosphate
availability during exercise and enhancing high-intensity (anaer-
obic) exercise capacity (1). That creatine is not prohibited by the
governing bodies of sport (including the World Anti-Doping
Agency) and is purported to be safe (1,5) likely contributes to
its widespread use.
The recognized potential of creatine to stimulate muscle
strength and power, to increase muscle volume/fat-free mass,
and to stimulate recovery from exercise (5) makes it particu-
larly attractive in sports with repeated short bursts of high-
intensity activity. Evidence of an ergogenic effect of the
supplement has repeatedly been reported in team sports, including
soccer (6). Further, in semiprofessional soccer players, a stan-
dard 8-wk course of creatine monohydrate (CM) supplementa-
tion has been reported to be safe (7). However, no study has so
far evaluated the possible adverse effect of creatine on lung
function in athletes. This is particularly striking considering
that, in an animal model of asthma, creatine has been shown
to exacerbate allergic-induced lung inflammation, airway re-
modeling, and airway hyperresponsiveness (AHR) (8). Creatine
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is thought to initiate an important cellular signaling pathway in
the airway epithelium that results, among others, in an increased
infiltration of inflammatory cells to the airways, an increased
number of mucus-synthesizing cells, and an upregulation of air-
way remodeling (9). Similar features have been observed in
bronchial biopsies of elite athletes (10,11), many of whom suf-
fer from asthma/AHR (10–13).
Asthma is a chronic inflammatory disorder of the airways,
with associated allergic sensitization, that is characterized by
reversible airway obstruction and AHR to a wide range of
stimuli (including exercise). In elite sports, asthma/AHR is
the most common chronic medical condition, with an overall
prevalence of ~8% (12). The distribution of asthma/AHR in
sport is however largely skewed, with the highest prevalence
rates observed in endurance sports and/or in disciplines
performed in unfavorable environments (e.g., swimming
or cross-country skiing) (12–14). Nonetheless, recent reports
have highlighted that team sport players, such as soccer
(15,16) and rugby players (17,18), may also commonly suffer
from asthma/AHR. Given the high prevalence of asthma-related
problems and the widespread use of creatine supplements in
elite sport, it is important to identify any adverse effects that
ergogenic food supplements may have on lung function in
this population.
The aim of our study was therefore to evaluate the effects of
a standard course of creatine supplementation on the respira-
tory health of youth elite athletes. Our hypothesis was that
ingestion of a standard dose of CM for 8 wk, in combination
with intensive soccer-specific training, increases airway in-
flammation and airway responsiveness.
METHODS
Study Participants
Nineteen under 18 (U18) and nine under 21 (U21), non-
smoking, male, elite soccer players from Watford Football
Club (FC) Academy agreed to take part in this project. Partic-
ipants completed a medical questionnaire before the start of
the study to check that none were currently injured or on
medication (except for asthma and/or exercise-induced bron-
choconstriction [EIB]). On enrolment, one participant disclosed
doctor-diagnosed asthma and, based on skin prick testing (cf.
methodology below), 19 (68%) had evidence of atopy. The
study was approved by the Research Ethics Committee from
the School of Sport and Education, Brunel University London
(no. RE69-13). All participants gave written informed consent
before taking part.
Study Design
A stratified, randomized, double-blind, placebo-controlled,
parallel-group trial of creatine supplementation was conducted
over 8 wk during the first half of the English competitive sea-
son (October–December). Stratified randomization was used
to ensure equal distribution between groups of (i) participants
with allergic sensitization (atopy) or doctor-diagnosed allergic
asthma and (ii) U18 and U21 players. Atopy was assessed at
study entry by standard skin prick test (19), with the following al-
lergens tested: house dust mite, timothy grass, silver birch, dog
hair, and cat hair. In line with current international recommenda-
tions (19), wheal diameters ≥3 mm were considered as positive.
All players abstained from caffeine and alcohol on the day
of the tests, from exercise for at least 4 h, and from antihista-
mines for 72 h. To control for diurnal variation in lung func-
tion, all tests were conducted in the morning/early afternoon.
Supplementation
Participants were randomized into groups by an indepen-
dent third party, using a random number generator. Allergic
and nonallergic players as well as U18 and U21 players were
allocated, in equal numbers, to the creatine and placebo groups.
A typical CM supplementation protocol was followed (1),
whereby participants ingested 0.3 g·kg−1⋅d−1 of CM (MyProtein,
Informed Sports Range, 100% pure) during a 1-wk loading
phase. The placebo group received the same dosage of malto-
dextrin (MyProtein, Informed Sports Range, 100% pure). The
supplement was combined with 90 g of the participant’s usual
protein drink (Maxiraw Protein Complex; 60% whey protein
concentrate, 20% soy protein isolate, and 20%micellar casein)
provided to the players at Watford FC Academy and ingested
in four daily 150-mL intakes. This was followed by a 7-wk
maintenance phase during which players ingested 5 g·d−1 of
CM, or of placebo, mixed up in 30 g of protein drink, and
taken at the end of their daily training session or after games
(at the weekend). To ensure adherence, the protein with sup-
plement drinks were prepared daily by the Head Academy
Sport Scientist (PS) at Watford FC Academy and handed out
directly to the players at the required times (except on Sun-
days, when players were provided with shakers to take home).
The body mass of the participants was measured using a
calibrated electronic scale pre- and postsupplementation.
Body composition was assessed via skinfold measurement.
In line with the International Society for the Advancement
of Kinanthropometry, eight sites (i.e., triceps, subscapular, bi-
ceps, iliac crest, supraspinal, abdominal, front thigh, and me-
dial calf ) were measured. All measurements were taken by a
researcher with level 1 qualification from the International
Society for the Advancement of Kinanthropometry (with an
average technical error of measurement of 1.50% ± 0.31%).
Diet was not standardized, but participants were asked not
to change their dietary habits during the study. None of the
players declared using creatine supplements in the 3 months
before the study.
Daily record of asthma symptoms, upper or lower respira-
tory tract infection symptoms, use of asthma reliever medica-
tion (salbutamol), and other potential side effects (e.g.,
muscle cramps, musculoskeletal injury, and gastrointestinal
discomfort) were logged for all players.
Training Program
This research did not interfere with the training schedule de-
vised by the players’ coaches. The 8-wk training program










included ~11 h·wk−1 of soccer-specific training (i.e., technical
and tactical exercises), with little strength and conditioning
work (approximately one session of 50 min·wk−1). As part
of the Football League Youth Alliance, the U18 team had reg-
ular match fixtures over the course of the trial. Further, some
the U21 players played for Watford FC first team (which, at
the time of the study, was competing in the English Football
League Championship).
Lung Health Assessment
All the tests below were performed twice: once before and
once after the 8-wk supplementation period.
Airway inflammation. Fractional nitric oxide in exhaled
breath (FENO) was measured at rest using NIOX VERO
(Aerocrine, Solna, Sweden) and was used as a noninvasive
marker of airway inflammation (20). Players were asked to re-
frain from exercising, eating, and drinking for an hour before
the FENO measurements (21). As per standard recommenda-
tions (21), at least two measurements agreeing within 10% of
each other were recorded, and the mean of the two values
was calculated and used for analysis.
Lung function. Standard spirometry was performed at rest
in all players using the MicroLoop spirometer (Micromedical,
Kent, UK) to determine baseline lung volume and expiratory
flow rates. In accordance with the international recommenda-
tions (22), at least three technically acceptable forced vital ca-
pacity (FVC)maneuvers were performed (up to a maximum of
eight), with a minimum of two reproducible recordings (differ-
ence ≤ 150 m for forced expiratory volume in 1 s [FEV1] and
FVC). The highest FEV1 and FVC readings were kept for
analysis. Forced expiratory flow between 25% and 75% of
FVC was taken from the reproducible maneuver with the
highest sum “FEV1 + FVC.” The highest peak expiratory flow
from all acceptable maneuvers was kept for analysis. Predicted
values were calculated from the GLI-2012 equations (23).
AHR. A standard 6-min eucapnic voluntary hyperpnoea
(EVH) test with dry air was used to estimate the degree of air-
way responsiveness. The test was performed on a commer-
cially available system (EucapSys, SMTEC, Nyon, Swiss)
and involved 6 min of heavy breathing of a dry gas mixture
containing 5% CO2, 21% O2, and balance nitrogen (24).
Presupplementation, the target ventilation (V̇E) was set at
85% of predicted maximum voluntary ventilation (MVV) (24),
calculated as resting FEV1 multiplied by 30. Postsupplemen-
tation, the target V̇Ewas set at the achieved level during the initial
test. Participants failing to achieve the minimal recommended
threshold of 60% MVV (24) were noted and discussed in
the Results section. Before and at 2, 5, 10, 15, and 20 min
of recovery, FVC maneuvers were performed in duplicate.
The best FEV1 values from reproducible measurements were
kept for analysis. The maximal fall in FEV1 post-EVH
(expressed as % difference from baseline) was calculated as
an index of airway responsiveness. A test was considered pos-
itive for EIB if FEV1 fell by ≥10% from baseline over two
consecutive time points (24).
Data Analysis
Sample size. FENO was the primary outcome measure.
The statistical power was set at 80% and the alpha level at
5%. To detect a 10-ppb difference in FENO between the CM
and the placebo groups postsupplementation (in noninflamed
airways, a change of 10 ppb being considered clinically mean-
ingful [20]), with a within-group SD of 6 ppb and a control-to-
experimental participant ratio of 1, we calculated that a sample
size of 14 players would be required (i.e., seven players per
group). Taking account of an estimated dropout rate of 30%,
a minimum of 20 players was required.
Statistical analysis. Normal distribution was examined
using the Shapiro–Wilk test. Data were analyzed using unpaired
t-tests for between-group comparisons at the start of the trial and
for changes over the supplementation period (Δ values). A two-
way repeated-measures ANOVA (RM-ANOVA), with “group”
and “time” as the main factors, was used to test between- and
within-group differences during the trial. FENO data had skewed
distribution. As RM-ANOVA is robust and can tolerate data that
are nonnormally distributed with only a small effect on the type I
error rate, the statistical test was however retained. Spearman cor-
relation coefficient was calculated to determine the relationship
between baseline FENO and change in FENO after supplementa-
tion with CM. Considering that some previous investigations in-
dicated that the deleterious effects of creatine may be specific to
sensitized animals (8), post hoc analyseswere conducted (follow-
ing the same procedures as described above) in atopic players
only (n = 7 in the CM group and n = 8 in the placebo group).
The significance level was set at P < 0.05. A trend for statistical
significance was deemed at P < 0.10. Effect size was calculated
via partial eta-squared values (η2) for ANOVA and Cohen’s
d for t-tests. The magnitude of effect sizes was classified as
small, medium, and large for η2 > 0.01, 0.06, and 0.14, respec-
tively, and for d > 0.2, 0.5, and 0.8, respectively (25). Data
were analyzed using the Statistical Package for the Social Sci-
ences for Windows (version 24; SPSS Inc., Chicago, IL). Un-
less otherwise stated, data are presented as group mean ± SD.
RESULTS
Participant characteristics. Twenty-eight players
(19 U18 and 9 U21) were initially recruited, of whom 19
completed the study. Details regarding participant with-
drawals are provided in the CONSORT diagram (Fig. 1).
The only player with doctor-diagnosed asthma (treated by
inhaled corticosteroids and inhaled beta2-agonist at the time
of the study) withdrew because of an asthma exacerbation
before randomization. Out of the 19 players who completed
the full trial (13 U18 and 6 U21), 9 were in the CM group and
10 were in the placebo group.
At study entry, participants were 17.4 ± 1.6 yr of age, had a
stature of 178.3 ± 5.6 cm, and had a bodymass of 73.7 ± 5.3 kg.
No group differences were noted for age or anthropometry
(Table 1). Eight weeks of CM or placebo supplementation
did not significantly change the body mass of the players
(P = 0.421): in the CMgroup, 75.7 ± 4.6 kg presupplementation












versus 75.7 ± 4.6 kg postsupplementation; in the placebo group,
72.0 ± 5.5 kg presupplementation versus 72.3 ± 5.5 kg post-
supplementation. A significant time effect was however noticed
for body composition (P = 0.002, η2 = 0.436), with the sum of
eight skinfolds reduced from 64 ± 15 to 61 ± 15 mm post-
supplementation (and no group or interaction effect). The rela-
tive reduction in skinfold thickness was 5.5% ± 5.0% in the
CM group and 4.4% ± 6.1% in the placebo group (P = 0.678).
Fifteen (79%) players were atopic (Table 1), with grass being
themost common allergen for them. Twelve (63%) players were
positive to grass, six (32%) to house dust mite, five (26%) to dog
hair, five (26%) to cat hair, and two (11%) to silver birch.
One participant reported minor gastrointestinal discomfort
during the supplementation period; he was in the CM group.
None of the other players reported any side effects from ingesting
the supplements. Two players reported a history of respiratory
symptoms on exertion (i.e., chest tightness with/without cough)
(Table 1), with one assigned to the CMgroup; neither of them re-
ported an exacerbation of these symptoms or usage of asthma
drugs over the supplementation period.
FENO. The RM-ANOVA revealed no group or time effect
for FENO, but there was a trend for an interaction effect,
with a P value of 0.056 and an η2 value of 0.199 (the latter
indicating a large effect size). Post hoc tests showed that
FENO did not significantly change over the supplementation
period in the placebo group (P = 0.374), but there was a
trend, with a medium effect size, for an increase in the CM
group (P = 0.071, d = 0.695) (Fig. 2). A statistical trend, with
a large effect size in the direction of an unfavorable change
in FENO after CM (Δ FENO = 9 ± 13 ppb) compared with
PLA (Δ FENO = −5 ± 16 ppb), was also observed (P = 0.056,
d = 0.950) (Fig. 3). A significant positive relationship was
noted between baseline FENO and Δ FENO in the CM group
(rs
2 = 0.460, P = 0.045).
FIGURE 1—Outline of the study design. FENO, fractional nitric oxide in exhaled air.










Resting lung function.Resting lung function was normal
(i.e., >lower limit of normal) in all the players, except one
(Table 1, ID no. 14). This U18 player reported respiratory
symptoms during strenuous exercise and had a family history
of asthma, but no previous doctor diagnosis of asthma and/or
EIB. No statistically significant differences in resting spirometry
were observed between groups and/or times (i.e., pre- to
postsupplementation) (Table 2). Although there was a trend
for athletes in the CM group to have a larger resting FVC
(P = 0.053, η2 = 0.203), this trend disappeared when the
data were normalized for age, stature, and ethnicity (FVC %
predicted) (Table 2).
TABLE 1. Characteristics of study participants.
ID No. Age (yr) Team Body Mass (kg) Stature (cm) FEV1 (% pred.) FVC (% pred.) Atopy FENO (ppb) Post-EVH Max FEV1 fall (%) Respiratory Symptoms
CM
1 17 U18 79.2 180.5 102 107 − 14 6 −
2 16 U18 77.7 184.7 94 102 + 86 27 −
3 16 U18 74.6 187.3 104 106 + 23 8 −
4 16 U18 77.0 176.5 121 116 + 18 1 −
5 16 U18 68.5 175.5 102 96 + 20 2 −
6 17 U18 68.4 168.3 93 99 + 25 5 −
7 21 U21 79.3 184.5 115 120 − 18 5 −
8 19 U21 74.9 179.3 101 97 + 79 19 −
9 18 U21 81.5 183.5 108 110 + 84 9 +
Mean 17.3 NA 75.7 180.0 104 106 NA 40.8 9.1 NA
SD 1.7 NA 4.6 5.9 9 8 NA 31.9 8.3 NA
Placebo
10 16 U18 73.8 184.3 97 91 + 14 7 −
11 17 U18 70.7 173.0 114 104 + 21 9 −
12 16 U18 61.3 171.1 105 99 − 17 3 −
13 18 U18 66.0 170.8 98 98 − 35 4 −
14 16 U18 76.7 179.0 72 79 + 62 12 +
15 17 U18 67.0 170.5 109 100 + 17 11 −
16 17 U18 75.7 180.4 138 127 + 34 1 −
17 21 U21 78.1 177.5 103 100 + 18 4 −
18 19 U21 76.2 181.9 97 105 + 48 8 −
19 18 U21 74.4 179.0 93 91 + 18 3 −
Mean 17.5 NA 72.0 176.8 103 99 NA 28.4 6.2 NA
SD 1.6 NA 5.5 5.0 17 12 NA 16.1 3.7 NA
None of the players had a medical history of asthma and/or of EIB. No between-group differences were noticed at study entry.
FENO, fractional exhaled nitric oxide in exhaled air; NA, not applicable.
FIGURE 2—Fractional nitric oxide in exhaled air (FENO) in youth elite
soccer players before and after 8 wk of CM (squares) or placebo supple-
mentation (circles). Open symbols represent atopic players, and closed
symbols represent nonatopic players. Individual and mean values (with
95% confidence intervals) are shown. When atopic players only were an-
alyzed, the P value for the within-group difference in the creatine group
was 0.072.
FIGURE 3—Change in fractional nitric oxide in exhaled air (Δ FENO) in
youth elite soccer players over 8 wk of CM (squares) or placebo supple-
mentation (circles). Open symbols represent atopic players, and closed
symbols represent nonatopic players. Individual and mean values
(with 95% confidence intervals) are shown. When atopic players only
were analyzed, the P value for the between-group difference was sig-
nificant at 0.026.












AHR. During the EVH tests, players sustained mean V̇E
values of 114 ± 23 L⋅min−1 presupplementation and
115 ± 25 L⋅min−1 postsupplementation in the CM group
and 94 ± 18 L⋅min−1 presupplementation and 96 ± 17 L⋅min−1
postsupplementation in the placebo group. The statistical trend
in the direction of a greater V̇E in the CM compared with the
placebo group (P = 0.063, η2 = 0.188) disappeared when the
data were expressed as % of predicted MVV (P = 0.514). V̇E
values were 71% ± 10% of predicted MVV presupple-
mentation and 73% ± 11% of predicted MVV postsupple-
mentation for the CM group versus 68% ± 13% of predicted
MVV presupplementation and 69% ± 13% of predicted MVV
postsupplementation for the placebo group. The supplementa-
tion had no effect on V̇E (i.e., no time or interaction effect).
Three U18 players were unable to reach the minimum target
V̇E of ≥60% of predicted MVV presupplementation (with
recorded V̇E at 59%, 58%, and 37% of predicted MVV).
Postsupplementation, two of these players reached the min-
imum threshold, whereas the latter only managed 40% of
predicted MVV.
The RM-ANOVA revealed no significant group or time ef-
fect on the maximum fall in FEV1 post-EVH, but a trend for an
interaction effect was noticed (P = 0.086, η2 = 0.163, large ef-
fect size). Post hoc tests showed no significant changes in the
fall in FEV1 over the supplementation period in the CM group,
but a trend, with a medium effect size, for a reduced fall in
FEV1 in the placebo group was found (P = 0.060, d = 0.679)
(Fig. 4). Further, the fall in FEV1 recorded postsupplementation
was larger by trend, with a large effect size, in the CM
group (9.7% ± 7.5%) compared with the placebo group
(4.4% ± 1.4%) (P = 0.070, d = 0.975) (Fig. 4).
At an individual level, three players (Table 1, ID nos. 2, 8,
and 14) had a ≥10% fall in FEV1 over at least two consecutive
time points after EVH (consistent with a diagnosis of EIB)
presupplementation; two of these players (both under CM)
had also a sustained fall in FEV1 postsupplementation (Fig. 4).
None of the three players with a positive EVH test had a
history of asthma and/or EIB, but they all had abnormally
high FENO values (Table 1). The player who was positive
for EIB presupplementation but negative postsupplementation
(Table 1, ID no. 14) was the one who had an abnormally low
lung function at rest (at both time points) and who reported
respiratory symptoms during exercise; his data were consistent
with a diagnosis of mild asthma. Another player in the CM
group who reported occasional respiratory symptoms during
exercise (Table 1, ID no. 9) had a borderline response to
EVH (i.e., 9% fall in FEV1 presupplementation and a
nonsustained 11% fall postsupplementation) and markedly
increased FENO levels at both time points (84 and 96 ppb
pre- and postsupplementation, respectively); his overall
profile was therefore suggestive of mild, seasonal EIB.
Altogether, this suggests that 4 (21%) of the 19 players
had undiagnosed asthma and/or EIB.
Post hoc analysis in atopic participants (n = 15).
Similar to the whole group analysis, an RM-ANOVA con-
ducted on FENO measurements revealed a significant inter-
action effect in the atopic players (P = 0.029, η2 = 0.317).
Post hoc tests showed a trend, with a large effect size, for
FENO to increase after supplementation with CM (P = 0.072,
d = 0.824) and no change after placebo (P = 0.248) (Fig. 2).
The statistical trend for a between-group difference for the
change in FENO over the supplementation period was signifi-
cant in atopic players (P = 0.029), with a large effect size
(d = 1.272): Δ FENO = 12 ± 14 ppb in the CM group versus
−6 ± 14 ppb in the placebo group (Fig. 3).
Trend for within- and between-group differences in airway
responsiveness reached statistical significance when atopic
athletes only were entered into the analysis. For the maximum
fall in FEV1 post-EVH, the RM-ANOVA revealed a signifi-
cant interaction effect (P = 0.027, η2 = 0.323). Post hoc tests
TABLE 2. Resting lung function data in youth elite soccer players before and after 8 wk of
CM or placebo (PLA) supplementation.
CM (n = 9) PLA (n = 10)
Pre-CM Post-CM Pre-PLA Post-PLA
FEV1 (L) 4.56 ± 0.79 4.52 ± 0.84 4.06 ± 0.76 4.04 ± 0.75
FEV1 (% pred.) 104 ± 9 103 ± 10 103 ± 17 101 ± 17
FVC (L) 5.43 ± 1.03* 5.43 ± 1.03 4.57 ± 0.78 4.58 ± 0.74
FVC (% pred.) 106 ± 8 105 ± 8 99 ± 12 99 ± 12
FEV1/FVC (%) 84 ± 4 83 ± 5 89 ± 6 88 ± 6
PEF (L⋅s−1) 9.73 ± 1.31 9.60 ± 1.35 9.05 ± 1.36 9.51 ± 1.51
FEF25–75 (L⋅s
−1) 4.66 ± 0.97 4.51 ± 1.10 4.62 ± 1.19 4.62 ± 1.36
Values are presented as mean ± SD.
*Trend for a higher presupplementation value compared with the placebo group
(P = 0.053).
PEF, peak expiratory flow; FEF25–75, forced expiratory flow between 25% and 75% of FVC;%
pred., % of the predicted values (37).
FIGURE 4—Pre- and postsupplementation fall in FEV1 after 6 min of
EVH of dry air in youth elite soccer players supplemented for 8 wk with
CM (squares) or a placebo (circles). Open symbols represent atopic
players, and closed symbols represent nonatopic players. Individual and
mean values (with 95% confidence intervals) are shown. When atopic
players only were analyzed, the P value for the within-group difference
in the placebo group was significant at 0.041.










showed no significant changes in the fall in FEV1 over the sup-
plementation period in the CM group (P = 0.297) but a reduced
fall in FEV1 in the placebo group (P = 0.041, d = 0.852)
(Fig. 4). Consequently, the change in AHR after the supplemen-
tation period was significantly different between the atopic
players supplemented with CM (−1.3% ± 3.0%) and placebo
(2.3% ± 2.6%) (P = 0.027, d = 1.289). Further, the fall in
FEV1 recorded postsupplementation was significantly larger
(P = 0.026, d = 1.295) in the CM group (11.4% ± 7.6%)
compared with the placebo group (4.5% ± 1.5%) in atopic
players (Fig. 4).
DISCUSSION
The aim of this study was to determine whether creatine
supplementation in combination with intensive training in-
creased airway inflammation and airway responsiveness in elite
athletes. In soccer academy players, trends for unfavorable
changes in FENO (an indirect marker of airway inflammation)
were noticed after daily ingestion of CM for 8 wk. A statistical
trend in the direction of a greater fall in FEV1 after dry air
hyperpnoea—indicative of increased airway responsiveness—
was also observed after CM supplementation compared with
placebo. These effects weremore pronouncedwhen atopic indi-
viduals only were entered into the statistical analysis. Therefore,
our findings highlight possible adverse effects of the popular
ergogenic food supplement on the airways of elite athletes,
particularly in those with allergic sensitization.
The safety of creatine has widely been investigated in ath-
letes through serum and urinary markers of metabolic, hepatic,
renal, and muscular function (e.g., [1,7]). The general consen-
sus is that, at the recommended dosage, creatine is safe (1,5).
However, up to now, the effects of creatine supplements on
lung function in athletes have not been assessed. In our study,
trends (with medium to large effect sizes) for an increase in
FENO (a well-established marker for eosinophilic airway in-
flammation in humans [20]) were observed after 8 wk of
CM supplementation in a mixed group of atopic and nonatopic
athletes. When atopic athletes (representing ~80% of the study
population) were analyzed separately, statistical significance
in favor of a larger increase in FENO postsupplementation in
the CM compared with the placebo group was noted. This is
in keeping with data obtained in a murine model for allergic
asthma (i.e., ovalbumin-treated mice) (8) that showed an in-
crease in airway inflammation (as identified by infiltration of
eosinophils and of proinflammatory cytokines within the air-
ways) and occurrence of airway remodeling after 32 d of creatine
supplementation. In chronically sensitized mice, low-intensity
aerobic exercise, however, reduced the exacerbatory effect of
creatine (26). The divergence in findings may be explained by
the intensity of exercise. Indeed, there is a growing body of ev-
idence of positive effects of regular physical activity on AHR in
the general population (27) and on airway inflammation (28)
and health-related quality of life in patients with asthma (29),
yet a detrimental effect of repeated, intensive physical training
on the airways of elite athletes (30,31).
At a cellular level, the proinflammatory effects of creatine
could be explained by an upregulation of an inflammatory cas-
cade and by an increased infiltration of cells (including eosin-
ophils) within the airways (9). In sensitized and nonsensitized
mice, creatine supplementation has been shown to increase the
epithelial expression of inducible nitric oxide synthase (9), i.e.,
the major determinant of FENO (32). This could therefore ex-
plain the trend for an increased FENO in the group supple-
mented with CM in our study. An upregulation of the airway
remodeling process was also noticed after creatine supplemen-
tation in both groups of mice (i.e., sensitized and nonsensitized)
(9). Signs of airway inflammation and remodeling (including
goblet cell hyperplasia and overexpression of mucin) have pre-
viously been observed in bronchial biopsies of elite athletes,
which were attributed to repeated exposure to high ventilation
in unfavorable environments (10,11). Whether an additive in-
flammatory effect could have arisen because of the use of cre-
atine supplements by some athletes is unknown.
In our study, the mild, unfavorable changes in FENO were
accompanied by a trend for increased airway responsiveness
(as measured by the fall in FEV1 post-EVH) in the group sup-
plemented with CM compared with the placebo. This trend be-
came significant when atopic athletes only were entered into
the analysis. As the maximum fall in FEV1 post-EVH was re-
duced in the atopic players after placebo but not CM supple-
mentation, creatine could somewhat alter the natural course
of airway responsiveness during a sporting season. It is not
the first time that fluctuations in airway responsiveness are ob-
served in elite athletes. Seasonal variability in the airway re-
sponse to exercise has previously been noticed in elite runners
(33) and elite swimmers (34), with AHR diminishing when
changes in environmental conditions and/or reductions in train-
ing load limited the stress to the airways. Although, in our
study, the within- and between-group differences in the fall
in FEV1 post-EVH were small and did not reach clinical sig-
nificance (i.e., no athletes under CM became positive for
EIB postsupplementation), the duration of the intervention
was relatively short (8 wk). We cannot exclude that subclin-
ical changes in airway responsiveness progress toward clin-
ical changes (i.e., asthma or EIB) when atopic athletes ingest
creatine chronically and/or do not adhere to the recom-
mended dosage.
Asthma/AHR is the most common chronic medical condi-
tion in elite sport (12,35). However, it is largely misdiagnosed
in professional (17,36) and recreational sports (37). In our
study, we found objective evidence of asthma and/or AHR
in about one in five youth players, but none had a medical his-
tory of asthma/EIB. In slightly younger (12–14 yr old) elite
soccer players, 4 (21%) out of 19 players were positive for
EIB when tested with EVH (15). These results therefore
highlight the need for implementing screening programs
for asthma/AHR in youth elite sport. This is all the more im-
portant in that cases of sudden fatal asthma exacerbations
have been reported after competitive and recreational sport-
ing activities, particularly in young (10–20 yr old) males
(38). Considering that 3 (23%) out of the 13 U18 players












in our study were not able to reach the minimum recom-
mended ventilatory threshold of 60% predicted MVV (24)
during the initial EVH test (an issue reported elsewhere
[15]), there is probably a need to revisit and validate the min-
imum required VE for EVH when testing youth athletes.
Although it is commonly accepted that creatine promotes
muscle mass gains during resistance training (1,5), in our
study, skinfold thickness was reduced postsupplementation
in both groups (whereas body mass remained unchanged).
This suggests that CM supplementation did not promote gains
in muscle mass beyond the effects observed with soccer train-
ing alone. This may be explained by the fact that (i) creatine
does not have a direct anabolic effect on protein synthesis
(39,40) and muscle hypertrophy (41), (ii) the benefits of the
supplement seem mainly dependent on an increased training
workload (42) and (iii) our groups were well matched for train-
ing load, and players spent limited time in the gym during the
supplementation period (~50 min of strength and conditioning
per week). Beyond asking participants to maintain the same
diet throughout the supplementation period, we were unfortu-
nately not in a position to control their food intake; this could
have influenced muscle creatine content (43) and responses to
the creatine supplement (5).
The strength of this study is the use of a rigorous methodo-
logical approach (i.e., a stratified, randomized, double-blind,
placebo-controlled, parallel-group study design) in a difficult-
to-reach sporting population (i.e., elite youth athletes). One
limitation that comes with inclusion of elite athletes is the rel-
atively large dropout rate (32%). Despite recruiting the entire
U18 and U21 squads, only 9 participants in the CM group
and 10 participants in the placebo group completed the full
trial. Further, although we met our recruitment target (based
on a priori sample size calculation), many of our data were
largely spread (including our primary research outcome,
FENO). Having asked all our participants to refrain eating
and drinking for 1 h before the FENO measurements (based
on the recommendations from the ATS/ERS [21]), we do
not think that food and beverages could explain the large inter-
individual differences in FENO. That the three participants
with the highest baseline FENO values were atopic and pre-
sented the largest increase in FENO after CM supplementation
suggest that individuals with underlying atopic airway inflam-
mation may be more responsive to the effects of creatine.
However, further studies (based around additional markers
of airway inflammation) are now warranted to evaluate the
clinical significance of these findings. This is particularly nec-
essary as a 20% increase in FENO is usually recommended as
a cutoff (rather than 10 ppb increase used in this study) to es-
tablish the effect of an intervention in individuals with raised
baseline values (i.e., FENO > 50 ppb [20]).
The large interindividual difference in our primary research
outcome (FENO) could also have contributed to several of our
P values not quite reaching the level of significance when an-
alyzing our mixed group of atopic and nonatopic athletes. To
overcome this limitation, two steps were taken: (i) effect sizes
were reported, with results suggesting that our intervention
(i.e., CM supplementation) had moderate to large effects on
FENO and on the fall in FEV1 post-EVH, and (ii) post hoc
analyses were conducted on atopic players only (n = 15),
which confirmed (or even reinforced) the original trends.
Therefore, in the absence of any other human-based data, we
cannot exclude a possible detrimental effect of CM on the air-
ways of elite athletes, especially in the atopic ones.
CONCLUSION
In summary, mild unfavorable changes in FENO were ob-
served in youth elite soccer players, particularly in those with
allergic sensitization, after a recommended 8-wk course of
CM supplementation. This observation was coupled with a
trend for the airways of athletes supplemented with CM to
be slightly more responsive to dry air hyperpnoea compared
with the placebo group postsupplementation. Until further
work is performed on the safety profile of creatine supple-
ments on lung function in humans, caution should prevail,
and monitoring of the respiratory health of elite athletes regu-
larly taking creatine supplements is advised.
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